PNC Financial Services Group
CPRX

PNC Financial Services Group’s Catalyst Pharmaceutical CPRX Stock Holding History

PNC Financial Services Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344K Buy
10,951
+397
+4% +$11.7K ﹤0.01% 2066
2026
Q1 		$261K Buy
10,554
+474
+5% +$11.3K ﹤0.01% 2146
2025
Q4 		$235K Buy
10,080
+714
+8% +$15.9K ﹤0.01% 2181
2025
Q3 		$185K Buy
9,366
+3,511
+60% +$72.2K ﹤0.01% 2357
2025
Q2 		$127K Buy
5,855
+354
+6% +$8.36K ﹤0.01% 2532
2025
Q1 		$133K Buy
5,501
+2,002
+57% +$45.1K ﹤0.01% 2467
2024
Q4 		$73K Buy
3,499
+289
+9% +$6.21K ﹤0.01% 2881
2024
Q3 		$63.8K Buy
3,210
+503
+19% +$9.32K ﹤0.01% 2949
2024
Q2 		$41.9K Buy
2,707
+125
+5% +$1.95K ﹤0.01% 3120
2024
Q1 		$41.2K Sell
2,582
-10,378
-80% -$156K ﹤0.01% 3085
2023
Q4 		$218K Buy
12,960
+1,719
+15% +$23.5K ﹤0.01% 2089
2023
Q3 		$131K Buy
11,241
+3,354
+43% +$44.9K ﹤0.01% 2394
2023
Q2 		$106K Buy
7,887
+4,728
+150% +$68K ﹤0.01% 2614
2023
Q1 		$52.4K Buy
3,159
+64
+2% +$1.06K ﹤0.01% 2974
2022
Q4 		$57.6K Buy
3,095
+315
+11% +$4.85K ﹤0.01% 2894
2022
Q3 		$36K Buy
2,780
+2,374
+585% +$28.1K ﹤0.01% 3154
2022
Q2 		$2K Hold
406
– – ﹤0.01% 4182
2022
Q1 		$4K Hold
406
– – ﹤0.01% 4044
2021
Q4 		$2K Buy
+406
New +$2.67K ﹤0.01% 4133
2019
Q4 		– Sell
-259,122
Closed -$1.38M – 4001
2019
Q3 		$1.38M Buy
+259,122
New +$1.38M ﹤0.01% 1127
2018
Q3 		– Sell
-1,000
Closed -$3K – 4124
2018
Q2 		$3K Buy
+1,000
New +$3.03K ﹤0.01% 3927
2015
Q3 		– Sell
-1,000
Closed -$4K – 4625
2015
Q2 		$4K Buy
+1,000
New +$3.99K ﹤0.01% 4151

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PNC Financial Services Group's CPRX Position: Q2 2026 in Review

PNC Financial Services Group increased its Catalyst Pharmaceutical (CPRX) stake by 3.8% in Q2 2026, buying an estimated $11.7K and bringing the position to 10,951 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #2066.

PNC Financial Services Group first reported a position in CPRX in Q2 2015 and has held it in 22 quarters since. The position peaked at $1.38M in Q3 2019. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • PNC Financial Services Group held 10,951 shares of Catalyst Pharmaceutical worth $344K as of Q2 2026.
  • PNC Financial Services Group bought 397 Catalyst Pharmaceutical shares in Q2 2026, an estimated $11.7K.
  • Catalyst Pharmaceutical made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #2066 holding.
  • PNC Financial Services Group first reported a position in Catalyst Pharmaceutical in Q2 2015 and has held it in 22 quarters since.
  • PNC Financial Services Group's Catalyst Pharmaceutical position peaked at $1.38M in Q3 2019.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.